drugset
drugset / Trial / NCT04055506

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

NCT04055506 ↗

Phase 1 Completed 16 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelHealth-services research

Summary

The Study of Cytochrome P450 1A2 Induction by Ritonavir on the drug effects of BMS-986165 in Healthy Participants

Timeline

Start
2019-08-14
Primary completion
2019-09-21
Completion
2019-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —
Subject Ritonavir Other / unclassified 100 mg —

Indications

No indication recorded.